Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Once-monthly ibandronate.

Toni M Dando1, Stuart Noble

  • 1Adis International Inc., Yardley, Pennsylvania, USA. demail@adis.com

Treatments in Endocrinology
|December 2, 2005
PubMed
Summary
This summary is machine-generated.

Once-monthly ibandronate (150 mg) is as effective as daily dosing for post-menopausal osteoporosis, improving bone mineral density and reducing fracture risk. Patients also preferred the monthly regimen for convenience.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trauma, identity and transition: evaluation of the RESLEAPS programme for retiring senior police officers.

Frontiers in psychiatry·2026
Same author

Spotlight on quetiapine in acute mania and depression associated with bipolar disorder.

CNS drugs·2006
Same author

Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder.

Drugs·2005
Same author

Low-dose ethinylestradiol/levonorgestrel.

Drugs·2005
Same author

Topical tazarotene: a review of its use in the treatment of plaque psoriasis.

American journal of clinical dermatology·2005
Same author

Spotlight on insulin aspart in type 1 and 2 diabetes mellitus.

Treatments in endocrinology·2005
Same journal

The replacement of human insulin with insulin analogs: a survey conducted in france to determine current and recommended practice.

Treatments in endocrinology·2006
Same journal

Is there a rationale for insulin therapy in pre-diabetic individuals?

Treatments in endocrinology·2006
Same journal

Optimizing the benefits of bisphosphonates in osteoporosis : the importance of appropriate calcium intake.

Treatments in endocrinology·2006
Same journal

Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women.

Treatments in endocrinology·2006
Same journal

A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.

Treatments in endocrinology·2006
Same journal

Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?

Treatments in endocrinology·2006
See all related articles

Area of Science:

  • Pharmacology
  • Osteoporosis Treatment
  • Bone Metabolism

Background:

  • Ibandronate is a nitrogen-containing bisphosphonate used for post-menopausal osteoporosis.
  • Efficacy may depend on cumulative dose rather than administration frequency.

Purpose of the Study:

  • To compare the efficacy and tolerability of once-monthly ibandronate with once-daily ibandronate.
  • To evaluate the effectiveness of ibandronate in reducing vertebral fracture risk.
  • To assess patient preference and convenience of monthly ibandronate.

Main Methods:

  • Large, randomized, double-blind, multicenter trials.
  • Comparison of once-monthly 150 mg ibandronate vs. once-daily 2.5 mg ibandronate.
  • Assessment of lumbar spine and hip bone mineral density (BMD) changes.

Related Experiment Videos

  • Evaluation of new vertebral fracture risk reduction.
  • Patient-reported outcomes on preference and convenience.

    • Main Results:

    • Once-monthly ibandronate was non-inferior to once-daily ibandronate in increasing lumbar spine and hip BMD.
    • Once-monthly ibandronate showed greater increases in lumbar spine BMD at 1 and 2 years.
    • Both daily and intermittent ibandronate significantly reduced vertebral fracture risk compared to placebo.
    • Adverse event profiles, including gastrointestinal events, were similar across treatment groups.
    • Significantly more women preferred once-monthly ibandronate over once-weekly alendronate.

    Conclusions:

    • Once-monthly ibandronate is an effective and well-tolerated treatment for post-menopausal osteoporosis.
    • The monthly dosing regimen offers comparable efficacy to daily dosing with improved patient convenience.
    • Ibandronate, in various oral dosing schedules, effectively increases BMD and reduces fracture risk.